AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 18685047
Drug: Pain Checker
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain Checker socks (active treatment)
Trial: 12844388
Drug: Low-Copper diet
RxNorm normalized name: Low-energy diets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-Copper diet (0.7 mg Cu/d)
Trial: 12844388
Drug: Medium-Copper diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium-Copper diet (1.6 mg Cu/d)
Trial: 12844388
Drug: High-Copper diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-Copper diet (6.0 mg Cu/d)
Trial: 8916559
Drug: BMS180048 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS180048 25 mg
Trial: 8916559
Drug: BMS180048 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS180048 50 mg
Trial: 8916559
Drug: BMS180048 75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS180048 75 mg
Trial: 8916559
Drug: BMS180048 (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BMS180048 (25 mg, 50 mg, 75 mg)
Trial: 25514686
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (group lyric analysis intervention)
Trial: 25514686
Drug: Verbal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verbal therapy (group talk therapy session)
Trial: 25514686
Drug: Wait-list control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wait-list control (eventually received group recreational music therapy intervention)
Trial: 22183938
Drug: gMS‐Classifier1 (panel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gMS‐Classifier1 (panel of four α‐glucose IgM antibodies)
Trial: 20637969
Drug: S/N +
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: S/N + S4 (sumatriptan 4 mg SC after S/N 85/500 mg)
Trial: 20637969
Drug: S/N +
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: S/N + S6 (sumatriptan 6 mg SC after S/N 85/500 mg)
Trial: 20637969
Drug: S100 +
RxNorm normalized name: ADU-S100
DrugBank: ADU-S100 (DB14722)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S100 + S100 (sumatriptan 100 mg PO, 2 tablets administered 2 hours apart)
Trial: 9469360
Drug: Serum HCG
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum HCG > 1,000 mIU/mL
Trial: 9469360
Drug: Serum HCG
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serum HCG ≤ 1,000 mIU/mL
Trial: 2229465
Drug: flurazepam 30
RxNorm normalized name: flurazepam 30 mg oral capsule
DrugBank: Flurazepam (DB00690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: flurazepam 30 mg
Trial: 2229465
Drug: flurazepam 15
RxNorm normalized name: flurazepam 15 mg oral capsule
DrugBank: Flurazepam (DB00690)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: flurazepam 15 mg
Trial: 713432
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of lysine salt of acetylsalicylic acid
Trial: 713432
Drug: Intramuscular administration
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of lysine salt of acetylsalicylic acid
Trial: 31586871
Drug: Specific exercise
RxNorm normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Specific exercise programme (balance and jump exercises), performed at least twice per week
Trial: 26142932
Drug: D3 500,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D3 500,000 IU administered orally as 50,000 IU daily for 10 consecutive days
Trial: 26142932
Drug: D2 600,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D2 600,000 IU single mega dose administered orally
Trial: 10671902
Drug: Sparfloxacin 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sparfloxacin 300 mg alone (Control)
Trial: 10671902
Drug: Sucralfate 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate 1.5 g every 12 h for five doses, with the fifth dose concurrently with sparfloxacin 300 mg (Treatment B)
Trial: 10671902
Drug: Sucralfate 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate 1.5 g every 12 h for five doses, with the fifth dose 2 h after sparfloxacin 300 mg (Treatment C)
Trial: 10671902
Drug: Sucralfate 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate 1.5 g every 12 h for five doses, with the fifth dose 4 h after sparfloxacin 300 mg (Treatment D)
Trial: 9348567
Drug: Oral UFT
RxNorm normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral UFT plus leucovorin
Trial: 8385216
Drug: alpha‐receptor blockade
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha‐receptor blockade
Trial: 29211308
Drug: Guadecitabine 60
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Guadecitabine 60 mg/m2 on 5 consecutive days (5-day regimen)
Trial: 29211308
Drug: Guadecitabine 90
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Guadecitabine 90 mg/m2 on 5 consecutive days (5-day regimen)
Trial: 29211308
Drug: Guadecitabine 60
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Guadecitabine 60 mg/m2 on 10 consecutive days (10-day regimen)
Trial: 25137863
Drug: Intravenous patient
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous patient controlled analgesia (PCA) with fentanyl
Trial: 25137863
Drug: Patient controlled
RxNorm normalized name: PATIENT CONTROLLED ANALGESIA VIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient controlled epidural analgesia (PCEA) with Bupivacaine 0.125% plus 2 microgram per ml fentanyl
Trial: 20733448
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C and E supplementation (1000 mg vitamin C and 400 IU vitamin E daily)
Trial: 18026149
Drug: High-dose melphalan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose melphalan (200 mg/m2) after cyclophosphamide (4 g/m2) for PBPC mobilization
Trial: 18026149
Drug: Conventional chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional chemotherapy (paclitaxel and carboplatin)
Trial: 10673876
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid 15 mg kg‐1 (n = 21)
Trial: 2181119
Drug: ticarcillin/clavulanate, 3.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ticarcillin/clavulanate, 3.1 g every six hours until clinical signs resolved
Trial: 2181119
Drug: cefoxitin, 2
RxNorm normalized name: CefOXitin, 2 g injectable powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cefoxitin, 2 g every six hours until clinical signs resolved
Trial: 7008891
Drug: Propranolol (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (1000 mg/day)
Trial: 31749128
Drug: AB-kefir (Bifidobacterium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AB-kefir (Bifidobacterium longum, Lactobacillus acidophilus, L. fermentum, L. helveticus, L. paracasei, L. rhamnosus, and Streptococcus thermophiles; total 10 log CFU/sachet) daily for 3 weeks
Trial: 28325472
Drug: High-dose-rate (HDR)
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose-rate (HDR) interstitial brachytherapy with one fraction of 19 Gy
Trial: 28325472
Drug: Low-dose-rate (LDR)
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose-rate (LDR) interstitial brachytherapy with 145 Gy
Trial: 23194084
Drug: Dapagliflozin 1
RxNorm normalized name: dapagliflozin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin 1 mg/day
Trial: 23194084
Drug: Dapagliflozin (1,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapagliflozin (1, 2.5, 5, or 10 mg/day)
Trial: 16542747
Drug: Cisplatin 75
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin 75 mg/m² on day 1 and gemcitabine 1,200 mg/m² on days 1 and 8, every 3 weeks for four courses (CG regimen)
Trial: 16542747
Drug: Mitoxantrone 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitoxantrone 10 mg/m² on day 1, methotrexate 35 mg/m² on day 1, and mitomycin 7 mg/m² on day 1, every 3 weeks with mitomycin in alternate cycles for four courses (MMM regimen)
Trial: 14515196
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg prinomastat plus gemcitabine/cisplatin (GC)
Trial: 14515196
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg prinomastat plus paclitaxel/carboplatin (PC)
Trial: 14515196
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg prinomastat alone (post‐discontinuation of chemotherapy)
Trial: 14515196
Drug: 5 or
RxNorm normalized name: Acys-5 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 or 10 mg prinomastat plus chemotherapy
Trial: 11198727
Drug: Oral erythromycin
RxNorm normalized name: Erythromycin
DrugBank: Erythromycin (DB00199)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral erythromycin ethyl succinate
Trial: 2935242
Drug: IA FUDR
RxNorm normalized name: magnesium aluminum silicate type Ia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IA FUDR (0.3‐0.1 mg/kg/day X 14, every 28 days)
Trial: 2935242
Drug: IV FUDR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV FUDR (0.05‐0.15 mg/kg/day X 14, every 28 days)
Trial: 27733522
Drug: Potassium nitrate
RxNorm normalized name: Potassium Nitrate
DrugBank: Potassium (DB14500)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Potassium nitrate (7 mg/kg body weight)
Trial: 1578948
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose ARA‐C (HDARAC) plus Asparaginase
Trial: 1578948
Drug: Idarubicin or
RxNorm normalized name: idarubicin Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Idarubicin or Daunorubicin in combination with Cytarabine in a standard 3+7 protocol
Trial: 1578948
Drug: Intermediate dose
RxNorm normalized name: Prevotella intermedia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate dose ARA‐A (IDARAC) plus Mitoxantrone
Trial: 1578948
Drug: Palliative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palliative treatment with Thioguanine and ARA‐C
Trial: 22782949
Drug: 15 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 µg adjuvanted vaccine
Trial: 22782949
Drug: 7.5 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 µg adjuvanted vaccine
Trial: 22782949
Drug: 3.75 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 µg adjuvanted vaccine
Trial: 22782949
Drug: 15 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 µg unadjuvanted vaccine
Trial: 8746180
Drug: Topical fluoridation
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical fluoridation with 2% NaF solution before orthodontic band cementation with zinc phosphate cement
Trial: 798330
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose intravenous methylprednisolone therapy at the time of kidney transplantation
Trial: 31567176
Drug: Potassium-sparing diuretics
RxNorm normalized name: Potassium
DrugBank: Potassium (DB14500)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Potassium-sparing diuretics (e.g., spironolactone)
Trial: 25386713
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (0.1 g·kg·d) during resistance training
Trial: 21530799
Drug: NO dietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NO dietary supplement Neo40 Daily®
Trial: 18427723
Drug: Tacrolimus (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus (oral, ≤3 mg once daily for 76 weeks)
Trial: 18427723
Drug: Mizoribine (previous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mizoribine (previous treatment)
Trial: 22089267
Drug: High-dose ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ibuprofen (20-10-10 mg/kg/day)
Trial: 22089267
Drug: Standard-dose ibuprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose ibuprofen (10-5-5 mg/kg/day)
Trial: 9648050
Drug: NNC 01-0687
RxNorm normalized name: NNC-55-0396 free base
DrugBank: NNC-55-0396 free base (DB17037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NNC 01-0687 (dopamine D1 antagonist)
Trial: 824215
Drug: Intravenous diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous diazepam (DZ)
Trial: 29227351
Drug: PECS block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PECS block with 30 ml of levobupivacaine 0.25% after induction of anaesthesia
Trial: 20545689
Drug: Dietary supplement
RxNorm normalized name: dietary supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplement (DS) containing Lactobacillus johnsonii (La1) and carotenoids for 10 weeks
Trial: 9974369
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (LMWH) - nadroparin, 85 anti-Xa IU/kg s.c. once daily
Trial: 9974369
Drug: Oral anticoagulant
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulant (OA) - acenocoumarol
Trial: 7673609
Drug: Lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole 30 mg once daily for 4 weeks, followed by famotidine 20 mg twice daily for 4 weeks
Trial: 7673609
Drug: Famotidine 20
RxNorm normalized name: famotidine 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Famotidine 20 mg twice daily for 4 weeks, followed by lansoprazole 30 mg once daily for 4 weeks
Trial: 2206878
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVGG) 800 mg/kg
Trial: 2206878
Drug: Intravenous albumin
RxNorm normalized name: albumin human, USP Injection [Albuminar]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous albumin
Trial: 7193003
Drug: Test preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test preparation A (Acetylsalicylic acid + glycine)
Trial: 7193003
Drug: Test preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test preparation B (Microencapsulated Acetylsalicylic acid)
Trial: 7193003
Drug: Both ASA
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both ASA preparations (1000 mg ASA)
Trial: 7193003
Drug: Test preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test preparation A
Trial: 7193003
Drug: Test preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test preparation B
Trial: 28789492
Drug: linagliptin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: linagliptin (5 mg/d)
Trial: 25808394
Drug: Pregabalin CR
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin CR 330 mg alone
Trial: 25808394
Drug: Pregabalin CR
RxNorm normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pregabalin CR 330 mg co-administered with erythromycin 500 mg
Trial: 12639353
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium 1 mg/kg IM
Trial: 12639353
Drug: Tramadol 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tramadol 1.5 mg/kg IM
Trial: 12639353
Drug: Eutectic mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eutectic mixture local anesthetic (EMLA) cream 15 g
Trial: 10674777
Drug: Atypical antipsychotics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atypical antipsychotics (risperidone, olanzapine)
Trial: 3889748
Drug: Aztreonam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aztreonam (2 g intravenously every eight hours) with clindamycin (600 mg intravenously every six hours)
Trial: 3889748
Drug: Gentamicin (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin (1.5 mg/kg intravenously every eight hours) with clindamycin (600 mg intravenously every six hours)
Trial: 3889748
Drug: Clindamycin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clindamycin (600 mg intravenously every six hours)
Trial: 23053638
Drug: EC‐D (epirubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EC‐D (epirubicin 90 mg/m(2) plus cyclophosphamide 600 mg/m(2) for 4 cycles followed by docetaxel 100 mg/m(2) × 4 cycles)
Trial: 23053638
Drug: EC‐DCb (epirubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EC‐DCb (epirubicin 90 mg/m(2) plus cyclophosphamide 600 mg/m(2) for 4 cycles followed by docetaxel 75 mg/m(2) plus carboplatin AUC 6 × 4 cycles)
Trial: 18589560
Drug: Memantine 10
RxNorm normalized name: Memantine 10mg Oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Memantine 10 mg
Trial: 2652084
Drug: Spiramycin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spiramycin (100 mg/kg/day for 10 days)
Trial: 582709
Drug: Domperidone 50
RxNorm normalized name: Domperidone
DrugBank: Domperidone (DB01184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Domperidone 50 mg
Trial: 22646975
Drug: Waiting-list control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting-list control group (no treatment)
Trial: 17982722
Drug: Fosfomycin (FOM)
DrugBank: Fosfomycin (DB00828)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fosfomycin (FOM) 2 g/dose, drip infused starting 30 min before surgery and twice daily for 3 days after surgery
Trial: 17982722
Drug: Cefotiam (CTM)
RxNorm normalized name: cefotiam
DrugBank: Cefotiam (DB00229)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefotiam (CTM) 1 g/dose, drip infused starting 30 min before surgery and twice daily for 3 days after surgery
Trial: 15342674
Drug: CETP inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CETP inhibitors
Trial: 11229617
Drug: delta9-THC (5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: delta9-THC (5.0 to 10.0 mg)
Trial: 7736528
Drug: Monoclonal antibodies
RxNorm normalized name: Monoclonal antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibodies against CA125
Trial: 7736528
Drug: Monoclonal antibodies
RxNorm normalized name: Monoclonal antibodies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal antibodies against TAG72
Trial: 2758104
Drug: Arbaprostil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arbaprostil (50 micrograms) and Aspirin (975 mg) coadministration
Trial: 2758104
Drug: Aspirin (975
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (975 mg) alone
Trial: 2758104
Drug: Salicylate pharmacokinetics
RxNorm normalized name: salicylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salicylate pharmacokinetics
Trial: 676309
Drug: Daily administration
RxNorm normalized name: Prevpac 30mg-500mg-500mg Daily Administration Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily administration of 1200 IU vitamin D3
Trial: 30670010
Drug: Amla extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amla extract (500 mg) administered twice daily for 12 weeks
Trial: 27193080
Drug: Intranasal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal fentanyl (1.5 mcg/kg) + intravenous tramadol (2 mg/kg)
Trial: 25311995
Drug: Ivacaftor 150
RxNorm normalized name: ivacaftor 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ivacaftor 150 mg every 12 hours
Trial: 15354916
Drug: 30 mL
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL of 0.5% bupivacaine with 1:200,000 epinephrine and 1 microg/kg of clonidine
Trial: 15354916
Drug: 30 mL
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL of 0.5% bupivacaine with 1:200,000 epinephrine (control group)
Trial: 8210255
Drug: CPT-11 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPT-11 (100 mg/m2 weekly intravenous infusion, regimen A)
Trial: 8210255
Drug: CPT-11 (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPT-11 (150 mg/m2 every two weeks, regimen B)
Trial: 802630
Drug: Diuretic plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diuretic plus methyldopa
Trial: 29065278
Drug: 3 mg·kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg·kg‐1 body mass caffeine
Trial: 29065278
Drug: 6 mg·kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg·kg‐1 body mass caffeine
Trial: 26694130
Drug: G-CSF (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (5 μg/kg/d Lenograstim from day 2 after each course of six chemotherapy courses)
Trial: 26694130
Drug: G-CSF- (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF- (no G-CSF administration)
Trial: 21773849
Drug: Hospital Medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hospital Medicine Physician Worklife Survey